Krazati® (adagrasib) – New indication
June 21, 2024 - The FDA approved Bristol Myers Squibb’s Krazati (adagrasib), in combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Top